These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1064685)

  • 41. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
    Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
    Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Action of cytosine arabinoside on human tumor cells isolated from malignant effusions: in vitro phosphorylation and inhibition of DNA synthesis.
    Stahel RA; Peter HJ; Sauter C
    Med Pediatr Oncol; 1979; 6(4):303-11. PubMed ID: 481320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 44. Clincal pharmacology of O2,2'-cyclocytidine.
    Rodriguez DH; Loo TL; Bodey GP; Freireich EJ
    Clin Pharmacol Ther; 1975 Jan; 17(1):66-72. PubMed ID: 1173058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mechanism of inactivation of cytosine arabinoside in human leukemic leukocytes in relation to clinical effects of the agent].
    Nakamura T; Shirakawa S; Sawada H; Inagaki A; Higuchi T
    Nihon Ketsueki Gakkai Zasshi; 1972 Apr; 35(2):121-30. PubMed ID: 4676722
    [No Abstract]   [Full Text] [Related]  

  • 46. Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system.
    Bottino J; McCredie KB; Ho DW; Freireich EJ; Buckles R; Herbst S; Lawson M
    Cancer; 1979 Jun; 43(6):2197-201. PubMed ID: 455216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A rapid enzymatic procedure for production of 1-beta-D-(3H)arabinofuranosyl cytosine 5'-triphosphate.
    Mintz CG; Agent C; Furlong NB
    Anal Biochem; 1976 Sep; 75(1):153-9. PubMed ID: 183566
    [No Abstract]   [Full Text] [Related]  

  • 48. [Patient with hypoplastic leukemia successfully treated with N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine].
    Uchida M; Tsutani H; Kagawa D; Ueda T; Domae N; Nakamura T
    Nihon Naika Gakkai Zasshi; 1985 Dec; 74(12):1709-13. PubMed ID: 3831195
    [No Abstract]   [Full Text] [Related]  

  • 49. In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine.
    Dedrick RL; Forrester DD; Ho DH
    Biochem Pharmacol; 1972 Jan; 21(1):1-16. PubMed ID: 4500983
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of CML blast crisis with low dose ARA-C.
    di Raimondo F; Milone G; Guglielmo P; Cacciola E; Giustolisi R
    Br J Haematol; 1985 Aug; 60(4):773-4. PubMed ID: 3861196
    [No Abstract]   [Full Text] [Related]  

  • 51. A hypothesis relating lymphocyte phosphorylation and transport of ara-C (cytarabine) to its antiviral activity.
    Gray GD; Renis HE
    J Theor Biol; 1973 Jun; 39(3):623-32. PubMed ID: 4354157
    [No Abstract]   [Full Text] [Related]  

  • 52. Molecular structure of 2,2'-anhydro-1- -D-arabinofuranosyl cytosine hydrochloride (cyclo ara-C): a highly rigid nucleoside.
    Brennan T; Sundaralingam M
    Biochem Biophys Res Commun; 1973 Jun; 52(4):1348-53. PubMed ID: 4717753
    [No Abstract]   [Full Text] [Related]  

  • 53. Enzymatic deamination of 8-azaguanine in normal and neoplastic tissues.
    HIRSCHBERG E; KREAM J; GELLHORN A
    Cancer Res; 1952 Jul; 12(7):524-7. PubMed ID: 14936026
    [No Abstract]   [Full Text] [Related]  

  • 54. Oxidative phosphorylation catalyzed by cytoplasmic particles isolated from malignant tissues.
    WILLIAMS-ASHMAN HG; KENNEDY EP
    Cancer Res; 1952 Jun; 12(6):415-21. PubMed ID: 14936006
    [No Abstract]   [Full Text] [Related]  

  • 55. Oxidative phosphorylation in homogenates of normal and tumor tissues.
    POTTER VR; LYLE GG
    Cancer Res; 1951 May; 11(5):355-60. PubMed ID: 14831080
    [No Abstract]   [Full Text] [Related]  

  • 56. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
    Gailani S; Nussbaum A
    J Med; 1976; 7(2):93-102. PubMed ID: 1064685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
    Mejer J
    Scand J Clin Lab Invest; 1982 Sep; 42(5):401-6. PubMed ID: 6961505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
    Nakamura T; Ueda T
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.